Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

@inproceedings{Tourneau2012EfficiencyON,
  title={Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents},
  author={Christophe Le Tourneau and Hui Kong Gan and Albiruni Ryan Abdul Razak and Xavier Paoletti},
  booktitle={PloS one},
  year={2012}
}
BACKGROUND Statistical simulations have consistently demonstrated that new dose-escalation designs such as accelerated titration design (ATD) and continual reassessment method (CRM)-type designs outperform the standard "3+3" design in phase I cancer clinical trials. METHODS We evaluated the actual efficiency of different dose escalation methods employed in first-in-human phase I clinical trials of targeted agents administered as single agents published over the last decade. RESULTS Forty… CONTINUE READING

1 Figure or Table

Topics